Catecholamine activity enhancer (CAE) structurally related to PPAP, operating by the same mechanism: enhancing spontaneous catecholaminergic neuronal activity rather than forcing release or blocking reuptake. It is generally considered more potent at lower doses, hence the 100µg microdose versus PPAP’s 20mg range, with potentially longer-lasting effects. Expected profile mirrors PPAP: context-dependent stimulation, no recreational value, no crash. Currently in testing phase with insufficient personal experience to characterize the subjective profile fully. Pharmacokinetics and long-term safety are poorly characterized as a research chemical with minimal human data.
More potent than PPAP at lower doses per the literature. Still accumulating personal data.